The RAS/RAF/MEK/ERK, as well as the KIT-activated pathways, have been demonstrated to be efficiently druggable, providing new therapy tools to limit tumor progression, particularly in patients that develop resistance to platinum-based treatments. This evidence concerns the gene MAP2K7 and neoplasm.